1 win onlineonewinpin-upmosbet aviatorpin up kz4r betmostbet kz1 вин авиаторaviator 1 winlucky jetparimatchpin up 777mostbet kzluckyjet1win lucky jet4rabetmosbet casinomosbet casinolucky jet onlinemostbet1 win casinolucky jet casinoslot 1winparimatch1 win indiamostbetpin up kzmostbet casino4a bet4r bet1win aviatormostbet casinopinupmostbetlacky jet1 winmastbetpin up casino onlinepin up casino indiamosbetmostbet1win1 winmostbet azpin uppinap1 winpin up1win slotsaviator1 win kz
?> ?> ?> ?> ?> ?>

LOS ANGELES– Although COVID-19 booster vaccinations in adults elicit high levels of neutralizing antibodies against the Omicron variant, antibody levels decrease substantially within three months, according to a new study published on Tuesday.

The findings, published in Cell Reports Medicine, are from a clinical trial sponsored by the U.S. National Institute of Allergy and Infectious Diseases.

As part of a “mix and match” clinical trial, researchers administered COVID-19 booster vaccines to adults in the United States who had previously received a primary COVID-19 vaccination series.

Researchers then evaluated immune responses over time.

They found that nearly all vaccine combinations evaluated elicited high levels of neutralizing antibodies to the Omicron BA.1 sub-lineage.

However, immune responses to Omicron in all groups waned substantially, with neutralizing antibody levels decreasing 2.4- to 5.3-fold by three months after booster shots, according to the study.

The researchers noted that the findings are consistent with real-world reports showing waning protection against SARS-CoV-2 infection during the Omicron wave in people who received a primary vaccine series plus a booster shot. – Xinhua